Skip to: Content
Skip to: Site Navigation
Skip to: Search

September 5, 2008 7:44:47 PM CDT

Learn about Newser Points »

Stories related to: Roche Holding

Stories

4 Stories

  • July 2008

    • Roche Makes Genentech Takeover Bid

      Wall Street Journal  |  Jul 21, 08 6:55 AM CDT

      Roche Makes Genentech Takeover Bid

      (Newser) - Swiss pharmaceutical company Roche today offered $43.7 billion for the outstanding shares of Genentech, the San Francisco-based biotech firm in which Roche already owns a 55.9% stake, the Wall Street Journal reports. The $89-a-share offer is the latest in a series of big pharma companies, whose new drug development has been lagging, stepping up investment in the more productive biotech sector. More »

      Tags

      mergers and acquisitions  • takeover  • Genentech  • Roche Holding

  • April 2008

    • Cancer Drug Sales Push Genentech Profits Up 12%

      Wall Street Journal  |  Apr 11, 08 8:28 AM CDT

      Cancer Drug Sales Push Genentech Profits Up 12%

      (Newser) - Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock edged up 0.3% in after-hours trading. More »

      Tags

      FDA  • breast cancer  • corporate earnings  • Genentech  • Avastin  • Roche Holding

  • November 2007

    • FDA May Add Warnings to Flu Meds

      Wall Street Journal  |  Nov 23, 07 4:12 PM CST

      FDA May Add Warnings to Flu Meds

      (Newser) - The FDA may change the labels of flu medications Tamiflu and Relenza to warn of serious side effects such as hallucinations, the Wall Street Journal reports. More than 700 so-called neuropsychiatric events—for example, children trying to "flee" by jumping through windows—and 16 deaths may be related to the drugs. Most reports come from Japan, where the drugs are most popular. More »

      Tags

      influenza  • side effects  • Tamiflu  • Roche Holding  • Relenza

  • August 2007

    • Biotech Giant Slashes Jobs

      Wall Street Journal  |  Aug 16, 07 1:34 AM CDT

      Biotech Giant Slashes Jobs

      (Newser) - Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune to the problems that plague traditional drug companies, the Wall Street Journal reports. More »

      Tags

      biotechnology  • Genentech  • restructuring  • Roche Holding  • Amgen

4 Stories

Today's Most Popular

Premium Articles from HighBeam

Find more articles like this

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »